$CATX
Perspective Therapeutics, Inc. Stock $catx

$catx Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000143774923032036 Filed on November 14, 2023

Income Statement

Concept	2023 Q4	2023 Q3	2022 Q3
Revenue	$1.434M	$2.185M	$1.717M
YoY Change	-22.07%	27.26%	-33.03%
Cost Of Revenue		$1.447M	$1.303M
YoY Change		11.05%	-15.11%
Gross Profit		$738.0K	$414.0K
YoY Change		78.26%	-59.77%
Gross Profit Margin		33.78%	24.11%
Selling, General & Admin	$21.06M	$5.551M	$3.914M
YoY Change	560.31%	41.82%	50.48%
% of Gross Profit		752.17%	945.41%
Research & Development	$21.31M	$5.721M	$708.0K
YoY Change	3512.03%	708.05%	0.85%
% of Gross Profit		775.2%	171.01%
Depreciation & Amortization	$272.0K	$269.0K	$68.00K
YoY Change	240.0%	295.59%	15.25%
% of Gross Profit		36.45%	16.43%
Operating Expenses	$42.38M	$11.27M	$4.622M
YoY Change	1021.03%	143.88%	39.93%
Operating Profit		-$10.53M	-$4.208M
YoY Change		150.33%	85.05%
Interest Expense	$833.0K	$14.00K	$140.0K
YoY Change	98.33%	-90.0%	351.61%
% of Operating Profit
Other Income/Expense, Net	$2.000K	$178.0K	$140.0K
YoY Change		27.14%	351.61%
Pretax Income	-$40.11M	-$10.36M	-$4.068M
YoY Change	1126.48%	154.57%	81.36%
Income Tax	-$2.651M	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$46.51M	-$10.36M	-$4.068M
YoY Change	1322.26%	154.57%	81.36%
Net Earnings / Revenue	-3243.24%	-473.96%	-236.92%
Basic Earnings Per Share		-$0.04	-$0.03
Diluted Earnings Per Share	-$0.17	-$0.04	-$28.63K
COMMON SHARES
Basic Shares Outstanding	280.6M	280.6M	142.1M
Diluted Shares Outstanding		28.06M

Balance Sheet

Concept	2023 Q4	2023 Q3	2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$9.238M	$17.98M	$54.11M
YoY Change	-78.91%	-66.77%	-12.28%
Cash & Equivalents	$9.238M	$18.00M	$18.99M
Short-Term Investments	$0.00		$35.12M
Other Short-Term Assets	$45.00K	$961.0K	$662.0K
YoY Change	-92.5%	45.17%	116.34%
Inventory		$1.013M	$1.553M
Prepaid Expenses
Receivables	$1.165M	$1.731M	$1.213M
Other Receivables	$10.00K	$0.00	$0.00
Total Short-Term Assets	$16.84M	$21.69M	$57.54M
YoY Change	-68.36%	-62.31%	-11.42%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.576M	$7.012M	$1.999M
YoY Change	231.12%	250.78%	2.36%
Goodwill	$24.06M	$27.32M
YoY Change
Intangibles	$354.0K	$50.00M
YoY Change
Long-Term Investments	$133.0K
YoY Change	-11.33%
Other Assets	$487.0K	$551.0K	$101.0K
YoY Change	106.36%	445.54%	-15.83%
Total Long-Term Assets	$81.05M	$88.83M	$4.998M
YoY Change	1562.31%	1677.31%	33.21%
TOTAL ASSETS
Total Short-Term Assets	$16.84M	$21.69M	$57.54M
Total Long-Term Assets	$81.05M	$88.83M	$4.998M
Total Assets	$97.89M	$110.5M	$62.54M
YoY Change	68.51%	76.72%	-8.98%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.107M	$3.867M	$2.495M
YoY Change	307.13%	54.99%	224.87%
Accrued Expenses	$4.436M	$4.200M	$1.506M
YoY Change	303.27%	178.88%	46.07%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$49.00K	$48.00K
YoY Change
Total Short-Term Liabilities	$15.66M	$8.115M	$4.001M
YoY Change	485.35%	102.82%	122.4%
LONG-TERM LIABILITIES
Long-Term Debt	$1.676M	$1.689M	$0.00
YoY Change
Other Long-Term Liabilities	$780.0K	$1.944M	$835.0K
YoY Change	-2.5%	132.81%	-27.52%
Total Long-Term Liabilities	$2.456M	$3.633M	$835.0K
YoY Change	207.0%	335.09%	-27.52%
TOTAL LIABILITIES
Total Short-Term Liabilities	$15.66M	$8.115M	$4.001M
Total Long-Term Liabilities	$2.456M	$3.633M	$835.0K
Total Liabilities	$22.71M	$11.75M	$4.836M
YoY Change	558.51%	142.93%	63.88%
SHAREHOLDERS EQUITY
Retained Earnings	-$152.4M	-$127.8M	-$102.7M
YoY Change	43.9%	24.48%	9.72%
Common Stock	$227.6M	$226.5M	$160.4M
YoY Change	41.75%	41.26%	0.65%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$75.18M	$98.77M	$57.70M
YoY Change
Total Liabilities & Shareholders Equity	$97.89M	$110.5M	$62.54M
YoY Change	68.51%	76.72%	-8.98%

Cashflow Statement

Concept	2023 Q4	2023 Q3	2022 Q3
OPERATING ACTIVITIES
Net Income	-$46.51M	-$10.36M	-$4.068M
YoY Change	1322.26%	154.57%	81.36%
Depreciation, Depletion And Amortization	$272.0K	$269.0K	$68.00K
YoY Change	240.0%	295.59%	15.25%
Cash From Operating Activities	-$9.008M	-$10.11M	-$1.763M
YoY Change	108.04%	473.45%	-15.4%
INVESTING ACTIVITIES
Capital Expenditures	$89.00K	$227.0K	$90.00K
YoY Change	48.33%	152.22%	66.67%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$3.000K	-$35.08M
YoY Change	-100.0%	-100.01%
Cash From Investing Activities	-$89.00K	-$227.0K	-$35.17M
YoY Change	-101.41%	-99.35%	65022.22%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	352.0K	1.000K	$28.00K
YoY Change		-96.43%
NET CHANGE
Cash From Operating Activities	-9.008M	-10.11M	-$1.763M
Cash From Investing Activities	-89.00K	-227.0K	-$35.17M
Cash From Financing Activities	352.0K	1.000K	$28.00K
Net Change In Cash	-8.745M	-10.34M	-$36.90M
YoY Change	-537.25%	-71.99%	1625.96%
FREE CASH FLOW
Cash From Operating Activities	-$9.008M	-$10.11M	-$1.763M
Capital Expenditures	$89.00K	$227.0K	$90.00K
Free Cash Flow	-$9.097M	-$10.34M	-$1.853M
YoY Change	107.22%	457.85%	-13.33%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	293000	usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	7000000
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	7000000
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	750000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	750000000
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	280571026
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	280571026
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	142112766
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	142112766
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-12000	usd
	dei	Document Type DocumentType	10-Q
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	276000	usd
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q3	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	311000	usd
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	233000	usd
	dei	Entity File Number EntityFileNumber	001-33407
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	41-1458152
	dei	Entity Address Address Line1 EntityAddressAddressLine1	350 Hills St., Suite 106
	dei	Entity Address City Or Town EntityAddressCityOrTown	Richland
	dei	Entity Address State Or Province EntityAddressStateOrProvince	WA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	99354
	dei	City Area Code CityAreaCode	509
	dei	Local Phone Number LocalPhoneNumber	375-1202
	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value
	dei	Trading Symbol TradingSymbol	CATX
	dei	Security Exchange Name SecurityExchangeName	NYSE
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	280571026
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17983000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	20993000	usd
CY2023Q3	us-gaap	Short Term Investments ShortTermInvestments	0	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	22764000	usd
CY2023Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1731000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1363000	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	1013000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	1409000	usd
CY2023Q3	us-gaap	Notes Receivable Net NotesReceivableNet	0	usd
CY2022Q4	us-gaap	Notes Receivable Net NotesReceivableNet	6109000	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	961000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	577000	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	21688000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	53215000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7012000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1684000	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1529000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	378000	usd
CY2023Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	182000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	182000	usd
CY2023Q3	us-gaap	Inventory Noncurrent InventoryNoncurrent	2237000	usd
CY2022Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	2396000	usd
CY2023Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	50000000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	0	usd
CY2023Q3	us-gaap	Goodwill Goodwill	27319000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	0	usd
CY2023Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	551000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	236000	usd
CY2023Q3	us-gaap	Assets Assets	110518000	usd
CY2022Q4	us-gaap	Assets Assets	58091000	usd
CY2023Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3867000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1541000	usd
CY2023Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	24000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	129000	usd
CY2023Q3	catx	Accrued Payroll And Related Taxes Current AccruedPayrollAndRelatedTaxesCurrent	3024000	usd
CY2022Q4	catx	Accrued Payroll And Related Taxes Current AccruedPayrollAndRelatedTaxesCurrent	212000	usd
CY2023Q3	us-gaap	Accrued Vacation Current AccruedVacationCurrent	548000	usd
CY2022Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	285000	usd
CY2023Q3	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	48000	usd
CY2022Q4	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	0	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	8115000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2676000	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1276000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	116000	usd
CY2023Q3	us-gaap	Long Term Notes Payable LongTermNotesPayable	1689000	usd
CY2022Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	0	usd
CY2023Q3	us-gaap	Asset Retirement Obligations Noncurrent AssetRetirementObligationsNoncurrent	668000	usd
CY2022Q4	us-gaap	Asset Retirement Obligations Noncurrent AssetRetirementObligationsNoncurrent	657000	usd
CY2023Q3	us-gaap	Liabilities Liabilities	11748000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	3449000	usd
CY2023Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	281000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	142000	usd
CY2023Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	226254000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	160432000	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-127765000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-105932000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	98770000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	54642000	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	110518000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	58091000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1909000	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1717000	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	5239000	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	7132000	usd
CY2023Q3	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	276000	usd
CY2022Q3	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	0	usd
	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	1097000	usd
	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	0	usd
CY2023Q3	us-gaap	Revenues Revenues	2185000	usd
CY2022Q3	us-gaap	Revenues Revenues	1717000	usd
	us-gaap	Revenues Revenues	6336000	usd
	us-gaap	Revenues Revenues	7132000	usd
CY2023Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1447000	usd
CY2022Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1303000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4863000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4351000	usd
CY2023Q3	us-gaap	Gross Profit GrossProfit	738000	usd
CY2022Q3	us-gaap	Gross Profit GrossProfit	414000	usd
	us-gaap	Gross Profit GrossProfit	1473000	usd
	us-gaap	Gross Profit GrossProfit	2781000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5721000	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	708000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15231000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2053000	usd
CY2023Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	855000	usd
CY2022Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	800000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2578000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2141000	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4696000	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3114000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	16792000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6277000	usd
CY2023Q3	catx	Gain Loss On Change In Aro Estimate GainLossOnChangeInAROEstimate	-0	usd
CY2022Q3	catx	Gain Loss On Change In Aro Estimate GainLossOnChangeInAROEstimate	-0	usd
	catx	Gain Loss On Change In Aro Estimate GainLossOnChangeInAROEstimate	15000	usd
	catx	Gain Loss On Change In Aro Estimate GainLossOnChangeInAROEstimate	-0	usd
CY2023Q3	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-0	usd
CY2022Q3	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-0	usd
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-22000	usd
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-0	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	11272000	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	4622000	usd
	us-gaap	Operating Expenses OperatingExpenses	34608000	usd
	us-gaap	Operating Expenses OperatingExpenses	10471000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-10534000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-4208000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-33135000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-7690000	usd
CY2023Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	204000	usd
CY2022Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	140000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	872000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	197000	usd
CY2023Q3	us-gaap	Interest Expense InterestExpense	14000	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	-0	usd
	us-gaap	Interest Expense InterestExpense	60000	usd
	us-gaap	Interest Expense InterestExpense	-0	usd
CY2023Q3	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	0	usd
CY2022Q3	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	0	usd
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	2000	usd
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	0	usd
CY2023Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-12000	usd
CY2022Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	0	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-12000	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	0	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	178000	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	140000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	802000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	197000	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-10356000	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4068000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-32333000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7493000	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-0	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-10500000	usd
	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	35076000	usd
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	22764000	usd
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-0	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-10356000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-4068000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-21833000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7493000	usd
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.08
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	280558000
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	142072000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	263236000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	142051000
	us-gaap	Net Income Loss NetIncomeLoss	-21833000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7493000	usd
	catx	Noncash Expense Lease NoncashExpenseLease	35000	usd
	catx	Noncash Expense Lease NoncashExpenseLease	4000	usd
	us-gaap	Depreciation Depreciation	684000	usd
	us-gaap	Depreciation Depreciation	197000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	298000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	0	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-22000	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-0	usd
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	30000	usd
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	26000	usd
	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	26000	usd
	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	25000	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-12000	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-0	usd
	catx	Accrued Interest On Short Term Investments AccruedInterestOnShortTermInvestments	-0	usd
	catx	Accrued Interest On Short Term Investments AccruedInterestOnShortTermInvestments	47000	usd
	catx	Gain Loss On Change In Aro Estimate GainLossOnChangeInAROEstimate	15000	usd
	catx	Gain Loss On Change In Aro Estimate GainLossOnChangeInAROEstimate	-0	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	3018000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	776000	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-10500000	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	368000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-434000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-257000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2015000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-12000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	128000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-656000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1647000	usd
	catx	Increase Decrease In Accrued Protocol Expense IncreaseDecreaseInAccruedProtocolExpense	78000	usd
	catx	Increase Decrease In Accrued Protocol Expense IncreaseDecreaseInAccruedProtocolExpense	49000	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-105000	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	22000	usd
	catx	Increase Decrease In Accrued Payroll And Related Taxes IncreaseDecreaseInAccruedPayrollAndRelatedTaxes	1170000	usd
	catx	Increase Decrease In Accrued Payroll And Related Taxes IncreaseDecreaseInAccruedPayrollAndRelatedTaxes	413000	usd
	catx	Increase Decrease In Accrued Vacation IncreaseDecreaseInAccruedVacation	-70000	usd
	catx	Increase Decrease In Accrued Vacation IncreaseDecreaseInAccruedVacation	12000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-27905000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6078000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	983000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	221000	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	18000	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	18000	usd
	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	-0	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1368000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-371000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	118028000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	532000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1199000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-11106000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	108653000	usd
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	2699000	usd
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	0	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	24462000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-35315000	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	56000	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	-0	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	554000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	28000	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	65000	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	-0	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	433000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	28000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3010000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-41365000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	21175000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	60536000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	18165000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	19171000	usd
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17983000	usd
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18989000	usd
CY2023Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	182000	usd
CY2022Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	182000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	18165000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	19171000	usd
	catx	Noncash Or Part Noncash Acquisition Value Of Assets Acquired Including Goodwill NoncashOrPartNoncashAcquisitionValueOfAssetsAcquiredIncludingGoodwill	85885000	usd
	catx	Noncash Or Part Noncash Acquisition Value Of Assets Acquired Including Goodwill NoncashOrPartNoncashAcquisitionValueOfAssetsAcquiredIncludingGoodwill	0	usd
	us-gaap	Stock Issued1 StockIssued1	54618000	usd
	us-gaap	Stock Issued1 StockIssued1	-0	usd
	catx	Noncash Or Part Noncash Acquisition Assumption Of Stock Options And Warrants NoncashOrPartNoncashAcquisitionAssumptionOfStockOptionsAndWarrants	-7836000	usd
	catx	Noncash Or Part Noncash Acquisition Assumption Of Stock Options And Warrants NoncashOrPartNoncashAcquisitionAssumptionOfStockOptionsAndWarrants	0	usd
	catx	Noncash Or Part Noncash Acquisition Notes Receivable And Accrued Interest Forgiven NoncashOrPartNoncashAcquisitionNotesReceivableAndAccruedInterestForgiven	-6171000	usd
	catx	Noncash Or Part Noncash Acquisition Notes Receivable And Accrued Interest Forgiven NoncashOrPartNoncashAcquisitionNotesReceivableAndAccruedInterestForgiven	0	usd
	us-gaap	Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1 NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1	17260000	usd
	us-gaap	Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1 NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1	0	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	557000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
	catx	Operating Lease Liability And Right Of Use Asset For New Lease OperatingLeaseLiabilityAndRightOfUseAssetForNewLease	811000	usd
	catx	Operating Lease Liability And Right Of Use Asset For New Lease OperatingLeaseLiabilityAndRightOfUseAssetForNewLease	0	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	64391000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	157000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-1347000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	63201000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	154000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-2078000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	61277000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	28000	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	465000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-4068000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	57702000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	54642000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	54553000	usd
CY2023Q1	catx	Adjustments To Additional Paid In Capital Assumption Of Stock Options And Warrants At Fair Value AdjustmentsToAdditionalPaidInCapitalAssumptionOfStockOptionsAndWarrantsAtFairValue	7836000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	22000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	451000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-10356000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	98770000	usd
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18000000	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-127800000	usd
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	pure
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><span style="text-decoration: underline; ">Use of Estimates</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The preparation of condensed consolidated financial statements in accordance with U.S. GAAP requires management of the Company to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes of the Company including: the fair value of net assets acquired in a business combination; the allowance for doubtful accounts receivable; net realizable value of the enriched barium inventory; the estimated useful lives used in calculating depreciation and amortization on the Company’s fixed assets, patents, trademarks, intangible assets and other assets; estimated amount and fair value of the asset retirement obligation related to the Company’s production facilities; equity method investment; and inputs to the Black-Scholes calculation used in determining the expense related to share-based compensation including volatility and estimated lives of options granted and impairment of long-lived assets including intangible assets and goodwill. Accordingly, actual results could differ from those estimates and affect the amounts reported in the financial statements.</p>
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	pure
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	50444000
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13452000
CY2023Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	764000	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	752000	usd
CY2023Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	229000	usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	636000	usd
CY2023Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	20000	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	21000	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	1013000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	1409000	usd
CY2023Q3	us-gaap	Inventory Noncurrent InventoryNoncurrent	2237000	usd
CY2022Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	2396000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	15313000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9315000	usd
CY2023Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	8301000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7631000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7012000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1684000	usd
CY2023Q3	us-gaap	Goodwill Goodwill	27300000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	0	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7268035
CY2022Q4	us-gaap	Goodwill Goodwill	0	usd
	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	27319000	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2023Q3	us-gaap	Goodwill Goodwill	27319000	usd
CY2023Q3	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	50000000	usd
CY2023Q3	catx	Indefinitelived Intangible Assets Accumulated Amortization IndefinitelivedIntangibleAssetsAccumulatedAmortization	0	usd
CY2023Q3	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	50000000	usd
CY2022Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	0	usd
CY2022Q4	catx	Indefinitelived Intangible Assets Accumulated Amortization IndefinitelivedIntangibleAssetsAccumulatedAmortization	0	usd
CY2022Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	0	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	451000	usd
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	465000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3018000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	776000	usd
CY2023Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	3896000	usd
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y9M18D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.72
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y10M13D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	4440000
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.34
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	72500
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.4
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	396885
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0.83
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	432450
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0.84
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10806200
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.56
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y2M4D
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	5953485
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.62
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y2M1D
CY2022Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10806200
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.56
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y11M4D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	13830000
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.51
	catx	Sharebased Compensation Arrangement By Sharebased Payment Award Options Assumed In Period Gross SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAssumedInPeriodGross	24263424
	catx	Sharebased Compensation Arrangements By Sharebased Payment Award Options Assumed In Period Weighted Average Exercise Price SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsAssumedInPeriodWeightedAverageExercisePrice	0.17
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1913185
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.29
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	1197899
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0.52
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1105138
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0.45
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	44683402
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.35
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y8M26D
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	2275000	usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	34880486
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.3
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y2M12D
CY2023Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	2275	usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	725000
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	4235000
CY2023Q3	catx	Sharebased Compensation Arrangement By Sharebased Payment Award Options Grants In Period Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue	265000	usd
CY2022Q3	catx	Sharebased Compensation Arrangement By Sharebased Payment Award Options Grants In Period Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue	1092000	usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	389599
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	170325
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	431250
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	100000
CY2023Q3	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	91605
CY2022Q3	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	72500
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	37000	usd
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	13830000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	4440000
	catx	Sharebased Compensation Arrangement By Sharebased Payment Award Options Grants In Period Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue	5611000	usd
	catx	Sharebased Compensation Arrangement By Sharebased Payment Award Options Grants In Period Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodFairValue	1139000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	1197899
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	396885
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1105138
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	432450
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1913185
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	72500
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	607000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.41
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	13830000
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.26
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	4440000
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2023Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y10M24D
CY2023Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.08	pure
CY2023Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	155000	usd
CY2022Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	79000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	355000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	235000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	98000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	430000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	562000	usd
CY2023Q3	us-gaap	Revenues Revenues	2185000	usd
CY2023Q3	us-gaap	Gross Profit GrossProfit	738000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	345000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	230000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	198000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1863000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	294000	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	1569000	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	293000	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1276000	usd
CY2022Q4	us-gaap	Asset Retirement Obligation AssetRetirementObligation	657000	usd
CY2021Q4	us-gaap	Asset Retirement Obligation AssetRetirementObligation	624000	usd
	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	26000	usd
	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	25000	usd
	catx	Gain On Change In Aro Estimate GainOnChangeInAroEstimate	-15000	usd
	catx	Gain On Change In Aro Estimate GainOnChangeInAroEstimate	0	usd
CY2023Q3	us-gaap	Asset Retirement Obligation AssetRetirementObligation	668000	usd
CY2022Q3	us-gaap	Asset Retirement Obligation AssetRetirementObligation	649000	usd
CY2023Q3	us-gaap	Notes Payable NotesPayable	1737000	usd
CY2022Q4	us-gaap	Notes Payable NotesPayable	0	usd
CY2023Q3	us-gaap	Notes Payable Current NotesPayableCurrent	48000	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	-0	usd
CY2023Q3	us-gaap	Long Term Notes Payable LongTermNotesPayable	1689000	usd
CY2022Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	0	usd
CY2023Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	12000	usd
CY2023Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	49000	usd
CY2023Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	52000	usd
CY2023Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	55000	usd
CY2023Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	1569000	usd
CY2023Q3	us-gaap	Long Term Debt LongTermDebt	1737000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-10534000	usd
CY2023Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	204000	usd
CY2023Q3	us-gaap	Interest Expense InterestExpense	14000	usd
CY2023Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	259000	usd
CY2022Q3	us-gaap	Revenues Revenues	1717000	usd
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	pure
CY2022Q3	us-gaap	Gross Profit GrossProfit	414000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-4208000	usd
CY2022Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	140000	usd
CY2022Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	67000	usd
	us-gaap	Revenues Revenues	6336000	usd
	us-gaap	Gross Profit GrossProfit	1473000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-33135000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	872000	usd
	us-gaap	Interest Expense InterestExpense	60000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	684000	usd
	us-gaap	Revenues Revenues	7132000	usd
	us-gaap	Gross Profit GrossProfit	2781000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-7690000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	197000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	197000	usd
CY2023Q1	us-gaap	Financing Receivable Allowance For Credit Losses Write Offs FinancingReceivableAllowanceForCreditLossesWriteOffs	6170000	usd
CY2023Q3	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	2185000	usd
CY2022Q3	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	2286000	usd
CY2023Q3	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-10356000	usd
CY2022Q3	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-7871000	usd
	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	6336000	usd
	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	8447000	usd
	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-27721000	usd
	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-11585000	usd

Files In Submission

Name	View Source	Status
0001437749-23-032036-index-headers.html	Edgar Link	pending
0001437749-23-032036-index.html	Edgar Link	pending
0001437749-23-032036.txt	Edgar Link	pending
0001437749-23-032036-xbrl.zip	Edgar Link	pending
catx-20230930.xsd	Edgar Link	pending
ex_583242.htm	Edgar Link	pending
ex_583243.htm	Edgar Link	pending
ex_583244.htm	Edgar Link	pending
ex_583245.htm	Edgar Link	pending
ex_594792.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
isr20230930_10q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
catx-20230930_def.xml	Edgar Link	unprocessable
catx-20230930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
isr20230930_10q_htm.xml	Edgar Link	completed
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
catx-20230930_cal.xml	Edgar Link	unprocessable
catx-20230930_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CATX
Perspective Therapeutics, Inc. Stock $catx

2023 Q4 Form 10-Q Financial Statement

#000143774923032036 Filed on November 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CATX Perspective Therapeutics, Inc. Stock $catx

2023 Q4 Form 10-Q Financial Statement

#000143774923032036 Filed on November 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CATX
Perspective Therapeutics, Inc. Stock $catx